BYVALSON (nebivolol hydrochloride; valsartan) by AbbVie is established. Approved for hypertension, to lower blood pressure, to lower blood pressure [see clinical studies ( )] and 2 more indications. First approved in 2016.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
BYVALSON is a fixed-dose combination oral tablet of nebivolol hydrochloride (beta-blocker) and valsartan (angiotensin II receptor antagonist) approved in 2016 for hypertension and heart failure. It works through multiple mechanisms: decreased heart rate and myocardial contractility via beta-blockade, suppression of renin activity, and vasodilation via angiotensin II receptor blockade. The dual mechanism addresses sympathetic and renin-angiotensin system pathways simultaneously.
Product faces patent expiration in ~1.5 years with significant competitive pressure (15 direct competitors), signaling potential team downsizing and transition from growth to defensive positioning.
established. Possible factors that may be involved include: (1) decreased heart rate, (2) decreased myocardial contractility, (3) diminution of tonic sympathetic outflow to the periphery from cerebral vasomotor centers, (4) suppression of renin activity and (5) vasodilation and decreased peripheral…
Worked on BYVALSON at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in ~2 years — expect lifecycle management and generic defense hiring
BYVALSON offers limited career growth opportunity given its LOE-approaching status and declining spending trajectory across competitors. Professionals joining this franchise should expect transition-focused roles centered on defensive strategies, pricing negotiations, and generic competition planning rather than growth initiatives.